Work for Quotient Limited?

Claim Your Profile

Quotient Limited Logo Image

Quotient Limited

Quotient Limited Banner Image

Most Recent Annual Report

Upgrade your company profile to unlock all of your annual report content on AnnualReports.com

2020 Annual Report and Form 10K

Quotient Limited

Quotient Limited has reached its limit for free report views.

Upgrade your company profile to unlock all of your annual report content on AnnualReports.com

Archived Annual Reports

About Quotient Limited

201-500 Employees
Based in Eysins, Switzerland

Building on over 30 years of experience in transfusion diagnostics, Quotient is a commercial-stage diagnostics company committed to delivering solutions that reshape the way diagnostics is practiced. MosaiQ, Quotient’s proprietary multiplex microarray technology, offers the world’s first fully automated, consolidated testing platform, allowing for multiple tests across different modalities. MosaiQ is designed to be a game-changing solution, which Quotient believes will increase efficiencies, improve clinical practice, deliver significant workflow improvements, and operational cost savings to laboratories around the world. A serological test was developed in April 2020 in response to the global COVID-19 pandemic. The MosaiQ COVID-19 Antibody Microarray is CE marked and is the subject of an Emergency Use Authorization issued by the U.S. Food and Drug Administration. The COVID-19 antibody test is available for distribution in the U.S., the EU, the UK and Switzerland. Quotient's operations are based in Eysins, Switzerland, Edinburgh, Scotland and Newtown, Pennsylvania.

Ticker:
QTNT
Exchange:
NASDAQ (See More NASDAQ Companies)
Industry:
Diagnostic Substances (See More Diagnostic Substances Companies)
Sector:
Healthcare (See More Healthcare Companies)

Looking for Other Annual Reports?

Search by company name or ticker symbol